MindWalk Holdings Corp. (NASDAQ:HYFT – Free Report) – Analysts at HC Wainwright decreased their Q2 2027 earnings per share (EPS) estimates for MindWalk in a report issued on Wednesday, September 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.05) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk’s Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at ($0.28) EPS.
MindWalk (NASDAQ:HYFT – Get Free Report) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%.The business had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.25 million.
Check Out Our Latest Research Report on MindWalk
MindWalk Price Performance
Shares of HYFT opened at $1.36 on Friday. The business’s 50-day moving average is $1.35 and its 200-day moving average is $1.37. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.84 and a quick ratio of 1.75. The company has a market capitalization of $63.53 million, a price-to-earnings ratio of -5.23 and a beta of 0.82. MindWalk has a fifty-two week low of $0.99 and a fifty-two week high of $2.99.
Hedge Funds Weigh In On MindWalk
An institutional investor recently bought a new stake in MindWalk stock. GSA Capital Partners LLP acquired a new stake in shares of MindWalk Holdings Corp. (NASDAQ:HYFT – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 34,525 shares of the company’s stock, valued at approximately $55,000. GSA Capital Partners LLP owned about 0.07% of MindWalk as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.70% of the company’s stock.
MindWalk Company Profile
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.
Featured Stories
- Five stocks we like better than MindWalk
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
